Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients

Victoria G Hall, Victor H Ferreira, Matthew Ierullo, Terrance Ku, Tina Marinelli, Beata Majchrzak-Kita, Anila Yousuf, Vathany Kulasingam, Atul Humar, Deepali Kumar, Victoria G Hall, Victor H Ferreira, Matthew Ierullo, Terrance Ku, Tina Marinelli, Beata Majchrzak-Kita, Anila Yousuf, Vathany Kulasingam, Atul Humar, Deepali Kumar

Abstract

Solid organ transplant recipients are at high risk of severe disease from COVID-19. We assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses of vaccine and immunogenicity assessed after each dose using the above tests. CD4+ and CD8+ T cell responses were assessed in a subset using flow-cytometry. A total of 127 patients were enrolled of which 110 provided serum at all time points. A positive anti-RBD antibody was seen in 5.0% after one dose and 34.5% after two doses. Neutralizing antibody was present in 26.9%. Of note, 28.5% of patients with anti-RBD did not have neutralizing antibody. T cell responses in a sub-cohort of 48 patients showed a positive CD4+ T cell response in 47.9%. Of note, in this sub-cohort, 46.2% of patients with a negative anti-RBD, still had a positive CD4+ T cell response. The vaccine was safe and well-tolerated. In summary, immunogenicity of mRNA-1273 COVID-19 vaccine was modest, but a subset of patients still develop neutralizing antibody and CD4+T- cell responses. Importantly polyfunctional CD4+T cell responses were observed in a significant portion who were antibody negative, further highlighting the importance of vaccination in this patient population. IRB Statement: This study was approved by the University Health Network Research Ethics Board (CAPCR ID 20-6069).

Keywords: clinical research/practice; infection and infectious agents - viral; infectious disease; vaccine.

© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

Figures

FIGURE 1
FIGURE 1
Study flow [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Antibody titer in transplant recipients pre-/post-immunization with each dose of mRNA-1273 (Moderna) COVID-19 vaccine and convalescent titers of transplant recipients after COVID infection. Horizontal lines represent median and interquartile range. Dotted red line represents positive cut-off value of assay at 0.8 U/mI [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3
FIGURE 3
Surrogate Vaccine Neutralization Assay results in transplant recipients pre-/post-immunization with each dose of mRNA-1273 (Moderna) COVID-19 vaccine [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4
FIGURE 4
Cell-mediated immune response in transplant recipients pre-/post-immunization with each dose of mRNA-1273 (Moderna) COVID-19 vaccine. Horizontal lines represent median and range. Dotted line is the limit of quantitation (LOQ; 0.01% or 100 per 106 cells). (A) Polyfunctional CD4+ T cell response. (B) Polyfunctional CD8+ T cell response [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 5
FIGURE 5
Local and systemic adverse effects within 7 days of mRNA-1273 COVID-19 vaccine in organ transplant recipients after the first and second doses (n = 108) [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020. 10.1093/cid/ciaa1097
    1. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20(7):1800–1808.
    1. Benotmane I, Risch S, Doderer-Lang C, Caillard S, Fafi-Kremer S. Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. Am J Transplant. 2021. 10.1111/ajt.16636
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–2206.
    1. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021. 10.1111/ajt.16615
    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920–1931.
    1. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. 2021;59(2):e02257-20. doi: 10.1128/JCM.02257-20.
    1. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–1078.
    1. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021;218(5):e20202617. doi: 10.1084/jem.20202617.
    1. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–462.
    1. Taylor SC, Hurst B, Charlton CL, et al. A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection. J Clin Microbiol. 2021;59(4):e02438-20. doi: 10.1128/JCM.02438-20.
    1. Hirzel C, L’Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant. 2021;21(6):2246–2253.
    1. L’Huillier AG, Ferreira VH, Hirzel C, et al. T-cell responses following natural influenza infection or vaccination in solid organ transplant recipients. Sci Rep. 2020;10(1):10104.
    1. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–599.
    1. Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Food and Drug Administration. Published 2007; Accessed May 22.
    1. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438.
    1. Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Investig. 2021;131(14):e150175. doi: 10.1172/JCI150175.
    1. Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021;40(8):754–758. doi: 10.1016/j.healun.2021.05.004.
    1. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278.
    1. Rabinowich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435–438.
    1. Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med. 2021;9(6):e52–e53.
    1. Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450.
    1. Assis RJA, Nakajima R, Jasinskas A, et al. Substantial differences in SARS-CoV-2 antibody responses elicited by natural infection and mRNA vaccination. bioRxiv. 2021. 10.1101/2021.04.15.440089
    1. Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 VACCINATION. N Engl J Med. 2021;384(1):80–82.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera